Stay updated with breaking news from Nasdaq Proc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Procaps Group (NASDAQ:PROC – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, “Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets […]
Procaps Group (NASDAQ:PROC – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Saturday, Zacks.com reports. According to Zacks, “Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional […]
Procaps Group (NASDAQ:PROC – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Zacks.com reports. According to Zacks, “Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets over-the-counter and prescription […]
Procaps Group S.A (NASDAQ:PROC – Get Rating) and FSD Pharma (NASDAQ:HUGE – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends. Profitability This table compares Procaps Group S.A and […]
Procaps Group S.A (NASDAQ:PROC – Get Rating)’s share price gapped down before the market opened on Monday . The stock had previously closed at $8.97, but opened at $8.32. Procaps Group S.A shares last traded at $8.21, with a volume of 300 shares. Several equities research analysts have commented on PROC shares. Zacks Investment Research […]